Article
Medicine, Research & Experimental
Yizhuo Xie, Zhihui Ren, Hongyu Chen, Huan Tang, Ming Zhu, Zhe Lv, Han Bao, Yan Zhang, Rui Liu, Yujia Shen, Yucui Zheng, Dongfanghui Miao, Xin Guo, Hongli Chen, Shanshan Wang, Jin Pei
Summary: This study designed a novel estrogen-targeted PEGylated liposome loaded with oxaliplatin and paclitaxel (ES-SSL-OXA/PTX) for the treatment of ovarian cancer. The results showed that ES-SSL-OXA/PTX had optimum specific targeting ability and exhibited a superior antiproliferative effect on SKOV-3 cells. The formulation also showed a prolonged half-life time, reduced toxicity, and promising potential for future clinical use in the treatment of ovarian cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Oncology
Michelle Tseng, Natalie Y. L. Ngoi, David S. P. Tan, Pearl S. Y. Tong
Summary: The management of advanced cervical cancer has evolved over time, with combined modality treatment involving surgery, radiotherapy, and systemic therapy showing improved outcomes. This article reviews recent advances and international guidelines in the management of cervical cancer.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Review
Oncology
Peng Liu, Guo-Fei Wang, Hua Peng, Lei Zhang, Xiao-Yan Li, Qiao-Miao Zeng, Qian Li, Jian-Hui Zhou
Summary: The study found that in the treatment of esophageal cancer, combining targeted agents with CRT can improve the PFS rate, but there is no significant benefit in terms of OS. Nimotuzumab was found to be superior to the control in terms of epCR and ORR.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Susan F. Dent, Amber Morse, Sarah Burnette, Avirup Guha, Heather Moore
Summary: HER2-targeted therapies have improved clinical outcomes in early and advanced breast cancer. Long-term studies have shown low rates of cardiotoxicity with these therapies, but cardiac monitoring is inconsistent in early breast cancer patients and almost non-existent in advanced breast cancer patients. More research is needed to determine the long-term cardiac safety of newer HER2 agents.
CURRENT ONCOLOGY REPORTS
(2021)
Article
Nanoscience & Nanotechnology
Yuxin Sun, Yizhuo Xie, Huan Tang, Zhihui Ren, Xue Luan, Yan Zhang, Ming Zhu, Zhe Lv, Han Bao, Yan Li, Rui Liu, Yujia Shen, Yucui Zheng, Jin Pei
Summary: A novel estrogen-targeted PEGylated liposome loaded with oxaliplatin was successfully prepared in this study, showing good targeting efficiency and strong anti-tumor activity in vitro and in vivo. Additionally, it significantly improved the metabolic behavior and toxicity profile of oxaliplatin.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Pharmacology & Pharmacy
Ishdeep Kaur, Terence Tieu, Veerasikku G. Deepagan, Muhammad A. Ali, Fahad Alsunaydih, David Rudd, Maliheh A. Moghaddam, Laure Bourgeois, Timothy E. Adams, Kristofer J. Thurecht, Mehmet Yuce, Anna Cifuentes-Rius, Nicolas H. Voelcker
Summary: Despite the clinical benefits of chemotherapeutics, drug resistance remains a major challenge in breast cancer treatment. Nanomedicines, such as porous silicon nanoparticles (pSiNPs), offer a targeted and effective approach by delivering multiple therapeutics and minimizing drug resistance. In this study, breast cancer-targeted pSiNPs co-loaded with an anticancer drug and gold nanoclusters (AuNCs) were engineered. The combination of hyperthermia and chemotherapy using targeted pSiNPs showed higher cell-killing efficacy compared to monotherapy and a nontargeted system with combined therapeutics. These findings highlight the potential of targeted pSiNPs as a versatile platform for personalized medicine.
Review
Oncology
Zhipeng Wu, Wei Wang, Lengyun Wei, Shenglong Zhu
Summary: This article aims to systematically analyze existing clinical trials, summarize the potential applications of metformin in cancer treatment, and propose three directions for its usage.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Editorial Material
Medicine, General & Internal
Hanna K. Sanoff
Summary: The cure rate for nonmetastatic rectal cancer has been improving over the years, with surgery, radiation therapy, and chemotherapy being the routine treatment. Recent studies have shown that adding multiagent chemotherapy to radiation therapy before proctectomy can significantly increase the 3-year disease-free survival rate. However, this treatment approach also comes with severe long-term sequelae.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Medicine, General & Internal
Lei Liu, Min Wang, Xianping Li, Sheng Yin, Bingqi Wang
Summary: Cervical cancer ranks fourth for both incidence and mortality, but there have been no major improvements in platinum-based chemotherapy for advanced cervical cancer. Novel agents are urgently needed to improve therapeutic effect. Breakthrough developments in targeted therapy research, including anti-angiogenesis and immune checkpoint inhibitors, offer promising new treatment options for cervical cancer.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Elizabeth B. B. Jeans, Daniel K. K. Ebner, Hirotoshi Takiyama, Kaitlin Qualls, Danielle A. A. Cunningham, Mark R. R. Waddle, Krishan R. R. Jethwa, William S. S. Harmsen, Joleen M. M. Hubbard, Eric J. J. Dozois, Kellie L. L. Mathis, Hiroshi Tsuji, Kenneth W. W. Merrell, Christopher L. L. Hallemeier, Anita Mahajan, Shigeru Yamada, Robert L. L. Foote, Michael G. G. Haddock
Summary: A comparative study between carbon-ion radiotherapy (CIRT) and multimodality therapy (CMT) for previously irradiated locally recurrent rectal cancer showed that CIRT has better overall survival rates at two and five years, equivalent local recurrence and disease progression rates, reduced treatment toxicity and lower patient cost. A prospective comparative study is needed to further evaluate the efficacy.
Review
Oncology
Yuedan Zhou, Sophie Espenel, Samir Achkar, Alexandra Leary, Sebastien Gouy, Cyrus Chargari
Summary: The standard treatment for locally advanced gynecological cancers is platinum-based concurrent chemoradiotherapy, but current chemotherapeutic drugs are only transiently effective and patients often develop resistance and distant metastases. This review discusses novel therapies that could work synergistically with conventional chemoradiotherapy, including anti-angiogenic agents, immunotherapy, tumor-infiltrating lymphocytes therapy, and apoptosis inducers. Radiosensitizers such as nanoparticles are also being tested to maximize the effect of radiotherapy locally.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Review
Immunology
Xin Zhao, Chenhao Zhang, Yi An, Zixuan Zhang, Jiahe Zhao, Xinwen Zhang, Yue Yang, Wei Cao
Summary: Despite the progress in RA treatment with various drugs, long-term use of these drugs may lead to additional side effects. Therefore, this paper reviews the research progress on liver damage caused by novel biological and targeted agents available for RA treatment, aiming to provide a reference for rational clinical administration of such drugs.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Lital Cohen, Yehuda G. Assaraf, Yoav D. Livney
Summary: Prostate cancer is a common cancer in older men and current treatments have limited efficacy. Researchers have developed targeted nanoparticles that can deliver drugs effectively and reduce toxic side effects.
Article
Chemistry, Physical
Xinguang Cao, Rui Li, Hui Wang, Changqing Guo, Saiqi Wang, Xiaobing Chen, Ruihua Zhao
Summary: In this study, six platinum(IV) complexes modified with indole-chalcone derivatives were synthesized and evaluated for their antiproliferative activities against colon cancer cell lines. The results showed that ICplatin-18, derived from oxaliplatin(IV), exhibited the most potent anticancer activity, reversed drug resistance, and selectively targeted cancer cells.
JOURNAL OF MOLECULAR STRUCTURE
(2023)
Article
Multidisciplinary Sciences
Yu Guo, Quan Wang, Yan Guo, Yiying Zhang, Yu Fu, Huimao Zhang
Summary: In this study, multi-modality radiomics was used to predict PNI status in rectal cancer, with CT score and T2WI score identified as independent risk predictors. A concise score combining these two factors showed the best performance.
SCIENTIFIC REPORTS
(2021)